Queensland Farmer Julianne McLean Seeks MND Trial Place

“It’s horrendous to watch.” Julianne McLean, a 49-year-old cattle farmer from Kilkivan, Queensland, is seeking to join a phase 2 clinical trial for NUN-004, a novel protein-based therapy for motor neurone disease (MND).

Developed from 25 years of research at the University of Queensland, the trial aims to stabilize nerve cell degeneration in 75 participants. Ms. McLean, who has been with her husband, Angus, for 30 years, was diagnosed with the condition in August after experiencing discomfort in her left leg, which progressed to difficulty walking, foot drop, and spinal and voice degeneration.

For patients like Ms. McLean, the diagnosis of MND—a progressive neurodegenerative condition—typically carries a life expectancy of three to five years, ABC News reported. The disease, also known as amyotrophic lateral sclerosis (ALS), results in the death of motor neurons, the nerve cells that transmit signals from the brain and spinal cord to muscles, causing progressive weakness and loss of function.

Clinical Insights into NUN-004

  • Mechanism of Action: The therapy is designed to inhibit the EphA4 receptor, a protein linked to the degeneration of motor neurons and the impairment of nerve repair processes.
  • Stabilization Potential: In an initial phase 1 study involving eight participants, researchers observed signs of clinical stabilization and anecdotal improvements in mobility and grip strength.
  • Trial Expansion: The upcoming phase 2 trial, supported by the biotechnology company NuNerve, will expand recruitment to 75 patients across sites in Queensland, New South Wales, and Western Australia.

“Currently, we don’t have a great understanding of what causes it,” said Antony Winkel, director of neurology at Sunshine Coast University Hospital (SCUH). Dr. Winkel noted that because the disease is progressive, the primary clinical objective is to halt further deterioration, as there is currently no known cure.

He added that the condition is “one of those really nasty diseases where it doesn’t matter what you do, you know the next day is going to be harder in some way.”

Farmer hopes mnd trial could give her more time with family
Photo: khanlist.com

While early results are encouraging, experts emphasize that phase 2 trials are essential to rigorously evaluate both safety and statistical efficacy in a larger, more diverse cohort.

Phase 1 tested safety; Phase 2 evaluates efficacy

Stacey Thorpe, chief executive of MND Queensland, characterized the trial as an “encouraging development” in a field where therapeutic options remain severely limited. The research is the result of 25 years of University of Queensland studies into how nerve cells communicate and repair themselves, moving from basic science toward a phase 2 clinical trial. “Developments like this provide genuine reasons for hope,” she said.

Consult neurologist for diagnostic workup

MND is a complex, multisystem disorder. Patients experiencing symptoms such as unexplained foot drop, muscle wasting, or difficulty with speech and swallowing should consult a neurologist for a formal diagnostic workup. Because NUN-004 is currently in a clinical trial setting, it is not available as a standard treatment; eligibility depends on strict inclusion and exclusion criteria defined by the trial protocol, including the stage of disease progression and existing comorbidities.

The University of Queensland was established by an Act of State Parliament in 1909 to commemorate the 50th anniversary of the state’s separation from New South Wales. As one of Australia’s six sandstone universities, it holds the distinction of being the oldest institution of its kind in the state.

Beyond its recent research, the university is known for its role in global scientific advancements, including the invention of the HPV vaccine. The institution also maintains a broad academic reach, incorporating over one hundred research institutes and centers that host programs ranging from molecular bioscience to bioengineering.

“Anytime you’re given a terminal diagnosis and that there’s officially no cure, the first thing that you lose is hope,” Ms. McLean told ABC News. Having farmed cattle and crops for more than 20 years, she noted that the physical nature of her work has become impossible due to compromised balance and strength.

She and her family are now focusing on the potential for the trial to extend her quality of life. “I know, as my body deteriorates, things will get harder and harder,” she said. “I’m just trying to stay focused on enjoying each day as much as possible.”

Photo of author

Health Desk

Health Desk at Archyde.

Diocese Architect Urges Lightning Rod Checks After Church Strikes